Meeting slides Multiple Myeloma 2009

Final meeting slides (click on title to download slides as pdf document)

Program Friday, May 15, 2009


13.05 – 13.30 Keynote lecture 
                    R. Kyle


SESSION I: Biology and prognostic Indicators
Chair: J. San Miguel

13.30 – 13.50 Phenotype of the myeloma cell. Clinical implications. 
                    J. San Miguel

13.50 – 14.10 Signal transduction and apoptosis. 
                    C. Pellat

14.10 – 14.30 The use of cytogenetics for defining prognosis and tailoring treatment 
                    J. Drach


SESSION II: The role of novel agents in front-line therapy in elderly patients
Chair: M. Boccadoro

14.30 – 14.50 Thalidomide 
                    C. Hulin

14.50 – 15.10 Bortezomib 
                    M.V. Mateos

15.10 – 15.30 Lenalidomide 
                    A. Palumbo


SESSION III: Fighting the disease: maximizing benefits while minimizing side-effects
Chair: H. Ludwig

16.30 – 16.50 Renal Failure 
                    H. Ludwig

16.50 – 17.10 The bone and the expert: what is the 2009 consensus? 
                    E. Terpos

17.10 – 17.30 Side effects of new therapies: how to prevent and handle 
                    M. Boccadoro


Program Saturday May 16, 2009

SESSION IV: The role of novel agents in the context of transplantation
Chair: JL Harousseau


08.30 – 08.50 Induction treatment prior to autologous stem cell transplantation 
                    M. Cavo

08.50 – 09.10 Novel agents given before and after autogolous stem cell transplantation 
                    M. Attal

09.10 – 09.30 The role of novel agents in allogeneic stem-cell transplantation 
                    N. Kröger


SESSION V: Treatment of relapsed disease
Chair: P. Sonneveld

10.10 – 10.30 How to design and interpret clinical trials in relapsed Multiple Myeloma: 
                    definition of the population and of the objectives 
                    M. Delforge

10.30 – 10.50 Novel agents in evaluation 
                    E. Ocio


SESSION VI: Current algorithms and future perspectives Chair: J. San Miguel

11.10 – 11.30 The use of new genetic tools for prognostication in Multiple Myeloma - `
                    introduction on risk-adapted strategy                   
                    H. Avet-Loiseau

11.30 – 11.50 Should complete remission be the primary objective of therapy? 
                   J-L. Harousseau

11.50 – 12.10 The role of continuous therapy: 
                    searching for the cure or changing Multiple Myeloma into a chronic disease. 
                    P. Sonneveld